Sarcopenia and sarcopenic obesity as prognostic predictors in hospitalized elderly patients with acute myocardial infarction

Natália de Moraes Santana, Roberta Maria Lins Mendes, Nadja Fernandes da Silva, Cláudia Porto Sabino Pinho
1 Universidade de Pernambuco, Recife, PE, Brazil.

DOI: 10.31744/einstein_journal/2019AO4632

OBJECTIVE: To investigate the potential value of sarcopenia and sarcopenic obesity as prognostic predictors in hospitalized elderly patients with acute myocardial infarction. METHODS: A cross-sectional study based on data collected from elderly patients with acute myocardial infarction, admitted to a public hospital located in the Northeastern region of Brazil, from April to July 2015. The diagnosis of sarcopenia was based on muscle mass, muscle strength and physical performance measurements. Cardiovascular risk and prognostic markers, such as troponin and creatine kynase MB isoenzyme values, acute myocardial infarction classification according to ST segment elevation, and thrombolysis in myocardial infarction score were used. RESULTS: The sample comprised 99 patients with mean age of 71.6 (±7.4) years. Prevalence of sarcopenia and sarcopenic obesity was 64.6% and 35.4%, respectively. Sarcopenia was more prevalent among males (p=0.017), older age group (p=0.008). Thrombolysis in myocardial infarction was the only marker of cardiovascular risk significantly associated with sarcopenia (p=0.002). CONCLUSION: Prevalence of sarcopenia was high and associated with thrombolysis in myocardial infarction risk score. Sarcopenic obesity affected approximately one-third of patients and was not associated with any of the prognostic predictors.

Keywords: Sarcopenia; Cardiovascular diseases; Myocardial infarction; Obesity; Aged

How to cite this article: Santana NM, Mendes RM, Silva NF, Pinho CP. Sarcopenia and sarcopenic obesity as prognostic predictors in hospitalized elderly patients with acute myocardial infarction. einstein (São Paulo). 2019;17(4):eAO4632.

http://dx.doi.org/10.31744/einstein_journal/2019AO4632

Corresponding author: Cláudia Porto Sabino Pinho
Rua dos Palmares, s/nº – Santo Amaro
Zip code: 50100-060 – Recife, PE, Brazil
Phone: (55 81) 99635-6615
E-mail: claudiasabinopinho@hotmail.com

Received on: June 14, 2018
Accepted on: Jan 21, 2019
Conflict of interest: none.

Conflict of interest: none.

Copyright 2019
This content is licensed under a Creative Commons Attribution 4.0 International License.
INTRODUCTION

Sarcopenia is a multifactorial geriatric syndrome, defined as progressive loss of muscle mass associated with reduced muscle strength and/or physical performance. Affected individuals may experience motor function compromise and loss of autonomy, with reduced quality of life and increased morbidity and mortality risks.\(^1\)\(^-\)\(^3\) Data on the incidence and prevalence of sarcopenia are scarce in Brazilian scientific literature. The prevalence of sarcopenia ranges from 5 to 50%;\(^3\) differences in reported prevalence may be due to a variety of factors, including different ethnic composition of samples, adoption of different criteria to define sarcopenia and/or different lean mass measurement methods.

Metabolic and cardiovascular risks (CVR) are closely related to aging and there is a growing interest in the study of associated factors, given cardiovascular diseases (CVD) are a major global cause of disability and death. Consistent associations between low muscle mass and risk of mortality have been demonstrated in some studies; however, potential associations between sarcopenia and CVD risk remain to be confirmed.\(^4\)\(^-\)\(^5\)

A recent review of clinical observational studies revealed associations between low muscle mass and arterial stiffness, an independent predictor of CVD. Also, sarcopenia may promote atherogenesis due to relative fat mass increase in response to loss of muscle mass and replacement of myocytes by adipocytes.\(^6\) Hence, sarcopenia in the presence of excess fat tissue, or sarcopenic obesity (SO), would have an even greater impact on metabolic diseases, CVD and mortality compared to obesity or sarcopenia alone.\(^7\)

Global aging population growth emphasizes the need to focus on adverse age-related conditions, such as sarcopenia and SO, as these are directly associated with loss of autonomy and potentially poorer cardiovascular prognosis.

OBJECTIVE

To investigate associations between sarcopenia and sarcopenic obesity as prognostic predictors in elderly patients with acute myocardial infarction.

METHODS

Retrospective study carried out at a public hospital, which is a reference in cardiology, located in the Northeastern region of Brazil, based on data collected from April to June 2015, and later, within two years of the first hospitalization. The sample comprised male and female patients aged ≥60 years, and hospitalized in the coronary care unit. Patients with physical (amputees) or cognitive (no eye contact with interviewer) impairments, bedridden, recovering from cardiac surgery, suffering from kidney disease and undergoing dialysis treatment, presenting with edema or unable to perform proposed tests (gait speed and handgrip strength - HGS) were excluded.

Assuming alpha and beta errors of 5% and 20%, respectively, 0.4 (p) correlation between muscle mass and length of hospital stay (based on a preliminary pilot study), and 0.15 variability (d²), the minimum sample size was set at 84 individuals. This number was increased by 20% (n=101 patients) to offset occasional losses.

Sarcopenia

Patients were assessed for sarcopenia within 48 hours of admission. Sarcopenia diagnosis was based on muscle mass, muscle strength and physical performance; sarcopenic patients were defined as those presenting with loss of muscle mass and concurrent decrease in muscle strength or physical performance. Pre-sarcopenia and severe sarcopenia were also accounted for. Pre-sarcopenia was defined as unfavorable lean mass assessment findings in non-sarcopenic patients (i.e., a stage preceding sarcopenia). Severe sarcopenia was defined according to three combined criteria: loss of muscle mass, loss of muscle strength and poor physical performance.\(^3\)

Muscle mass

Muscle mass estimates were based on a skeletal muscle mass index (SMMI), calculated using the following equation: 

\[
\text{SMMI} = \frac{\text{SMM}}{\text{height}^2}
\]

Skeletal muscle mass (SMM) was calculated according to Janssen et al.:\(^8\)

\[
\text{SMM} \ 0 \ (\text{kg}) = \left\{ \left[ \text{height}^2 \times \text{resistance} \times 0.401 \right] + \left( \text{sex} \times 3.825 \right) + \left( \text{age} \times -0.071 \right) \right\} + 5.102 \ (\text{height expressed in centimeters; resistance expressed in ohms; 1 and zero = male and female gender respectively; age given in years}).
\]

Muscle mass assessment criteria were based on SMMI cutoff values determined in NHANES III.\(^9\)
In that study, (9) 4,449 individuals aged ≥60 years were evaluated and SMMI <6.76kg/m² and <10.76kg/m² established as references for low muscle mass in women and men, respectively. (10) Resistance was determined by bioelectrical impedance analysis (BIA) performed using portable equipment (Biodynamics, model 310).

**Muscle strength**

Muscle strength was estimated from HGS measurements made using a digital dynamometer (JAMAR®). Cutoff values were determined according to HGS classification criteria proposed by Lauretani et al., (11) where HGS <30kg/f and <20kg/f, reflect unfavorable values for women and men, respectively.

**Physical performance**

Physical performance assessment was based on the gait speed test (walking speed timed over a predetermined 4-meter trajectory on a level surface); low and normal gait speeds were defined as < and >0.8 meters/second, respectively. The fastest out of two repetitions was used in the analysis. (12)

**Sarcopenic obesity**

Sarcopenic obesity was defined as abdominal circumference (AC) ≥88cm for women and ≥102cm for men, combined with a diagnosis of sarcopenia. (13)

Abdominal circumference was measured using a non-elastic measuring tape placed midway between the last rib and the iliac crest, and read to the nearest 0.1cm. (14) Bony landmarks were located and palpated by the examiner at the level of the axillary midline. The measuring tape was wrapped around the abdomen in the horizontal plane and kept strictly parallel to the ground. Measurements were made at end of a normal expiration with patients standing upright; the tape was kept close to the skin and no pressure applied. Two measurements were obtained per landmark. (15,16)

**Cardiovascular risk and prognostic markers**

The following variables were evaluated: troponin and creatine kinase MB isoenzyme (CKMB) values, acute myocardial infarction (AMI) classification according to ST segment elevation (ST segment elevation myocardial infarction, STEMI, or non-ST segment elevation myocardial infarction, NSTEMI), need for coronary angioplasty or myocardial revascularization, complications during hospital stay (infections, intensive care unit/ICU stay and/or death), length of hospital stay (days), readmission to the same unit (within 2 years of data collection, up to July 2017), thrombolysis in myocardial infarction (TIMI) scores reflecting risk of post-infarction complications (low, intermediate or high; zero to 2, 3 to 5, and >5, respectively) and mortality. (17) Comorbidities such as diabetes mellitus (DM) and hypertension (HTN) were also accounted for. C-reactive protein (CRP) >5.0mg/dL was selected among inflammatory markers associated with CVR. Clinical data were extracted from medical records.

**Sociodemographic variables**

The sociodemographic profile of the study population was delineated based on the following parameters: age, sex, race and level of education (years). Race/skin color (white, brown or black) (18) was determined by interviewers, then dichotomized into white and non-white for analytical purposes.

**Nutritional status**

Nutritional status was determined according to body mass index (BMI, body weight in kilograms divided by the square of height in meters) and the cutoff points proposed by Lipschitz, (19) (<22kg/m², 22 to 27kg/m² and >27kg/m², underweight, eutrophic and overweight, respectively) were adopted.

**Statistical analysis**

Data tabulation and analysis were carried out using Excel 2007 and the software Statistical Package for the Social Sciences (SPSS), version 13.0 (Chicago, IL, USA). Descriptive analysis of variables consisted of calculation of frequency distributions and measures of central tendency. Continuous variables were tested for normality using the Kolmogorov-Smirnov test. Normally distributed variables were expressed as mean and standard deviation, and analyzed using the parametric Student’s t test. Non-normally distributed variables (CKMB, troponin values and TIMI scores), were expressed as median and interquartile ranges, and analyzed using the non-parametric Mann Whitney
U-test. Associations between categorical variables were investigated using Pearson’s \( \chi^2 \) test. The level of significance was set at 5% (\( p<0.05 \)).

**Ethical aspects**

This study was approved by the Research Ethics Committee (CEP) for projects involving human beings of Hospital Universitário Oswaldo Cruz/Pronto-Socorro Cardiológico Universitário de Pernambuco Prof. Luiz Tavares, in compliance with resolution 466/12 of Conselho Nacional de Saúde/Ministério da Saúde [National Health Council/Ministry of Health], no. 980,370, CAAE: 41990815.6.00005192. Participants were duly informed of objectives of the study, data collected and potential risks and benefits derived from participation in the study. Volunteer participants signed an Informed Consent Form (ICF).

**RESULTS**

The final sample comprised 99 patients with AMI, after exclusions due to inconsistent data. Mean age was 71.6 (± 7.4) years; male and female patients were equally represented and non-white individuals prevailed (68.7%). Prevalence of hypertension and DM corresponded to 90.9% and 45.5%, respectively. Elevated CRP was detected in 67.4% of individuals and NSTEMI prevailed in the sample (73.2%). Mortality was 5.1%, 13.3% of patients required intensive care and 2.0% developed infections. Prevalence of malnourishment was 11.1%, whereas excess weight and abdominal obesity were detected in 41.4% and 52.4% of sample, respectively. Intermediate to high TIMI scores were attributed to 76% of the study population (Table 1).

Prevalence of sarcopenia was 64.6%, with 70.3% of severely sarcopenic patients. Pre-sarcopenia was diagnosed in 22.9% of non-sarcopenic patients. As regards components of the diagnostic criteria for sarcopenia, physical performance was the most severely compromised (84.3%), followed by low muscle mass and low muscle strength (73.7% and 63.6%, respectively). Approximately 35% of patients were diagnosed with SO (Table 2).

Analysis of associations between sarcopenia and CVR variables revealed higher prevalence of sarcopenia among male patients (76.0% and 53.1%, male and female patients, respectively); \( p=0.017 \) and increasing prevalence with age (93.3% prevalence in individuals

| Variable | n (%) |
|----------|-------|
| Sex      |       |
| Male     | 49 (49.5) |
| Female   | 50 (50.5) |
| Age, years |       |
| 60-69    | 42 (42.4) |
| 70-79    | 42 (42.4) |
| ≥80      | 115 (15.2) |
| Race     |       |
| White    | 31 (31.3) |
| Non-white| 68 (68.7) |
| Hypertension | 90 (90.9) |
| Diabetes mellitus | 45 (45.5) |
| Nutritional status |       |
| Underweight | 11 (11.1) |
| Eutrophic | 47 (47.5) |
| Overweight | 41 (41.4) |
| Abdominal obesity | 52 (52.4) |
| CRP      |       |
| Normal   | 29 (32.6) |
| Elevated | 60 (67.4) |
| AMI therapy |       |
| Clinical management | 56 (61.7) |
| Angioplasty | 17 (17.3) |
| Revascularization surgery | 25 (25.5) |
| Complications during hospital stay |       |
| Yes      | 20 (20.4) |
| No       | 78 (79.6) |
| AMI classification |       |
| STEMI    | 25 (25.8) |
| NSTEMI   | 71 (73.2) |
| Readmission |       |
| Yes      | 17 (17.2) |
| No       | 82 (82.8) |
| TIMI     |       |
| Low risk | 23 (24.0) |
| Intermediate risk | 56 (58.3) |
| High risk | 17 (17.7) |

CRP: C-reactive protein; AMI: acute myocardial infarction; STEMI: ST elevation acute myocardial infarction; NSTEMI: non-ST elevation acute myocardial infarction; TIMI: thrombolysis in myocardial infarction.

**Table 1. Sociodemographic and clinical features of elderly patients with coronary heart disease hospitalized at a cardiology reference center in the Northeastern region of Brazil**

| Variable | n (%) |
|----------|-------|
|Variable  |       |
| Sarcopenia |       |
| Yes      | 64 (64.6) |
| No       | 35 (35.4) |
| Sarcopenia classification |       |
| Sarcopenia | 19 (29.7) |
| Severe sarcopenia | 45 (70.3) |
| Classification of non-sarcopenic individuals |       |
| Non-sarcopenic | 27 (77.1) |
| Pre-sarcopenic | 8 (22.9) |
| Diagnostic components of sarcopenia |       |
| Reduced muscle mass* | 73 (73.7) |
| Reduced muscle strength† | 63 (63.6) |
| Low physical performance‡ | 75 (84.3) |
| Sarcopenic obesity |       |
| Yes | 35 (35.4) |
| No | 62 (62.6) |

* <6.76kg/m² for women and <10.76kg/m² for men; † <30kg/f for men and <20kg/f for women; ‡ <0.8 meters/second.

**Table 2. Characteristics of sarcopenia and sarcopenic obesity in elderly patients with coronary heart disease hospitalized at a cardiology reference center in the Northeastern region of Brazil**
aged 80 years or older, p=0.008). Thrombolysis in myocardial infarction score was the only CVR marker significantly associated with sarcopenia, with higher median scores attributed to sarcopenic individuals (5.0, IQR: 3.0-5.0 versus 3.0, IQR: 2.0-4.0; p=0.002) (Table 3).

Sarcopenic obesity was not associated with demographic variables or CVR (Table 4).

### Table 3. Associations among sarcopenia, sociodemographic and clinical variables, and prognostic markers of coronary heart disease risk in hospitalized elderly patients with coronary heart disease

| Variable                          | Sarcopenia | No sarcopenia | p value* |
|-----------------------------------|------------|---------------|----------|
| Sex                               | n          | %             | n        | %         |          |
| Male                              | 38         | 76.0          | 12       | 24.0      | 0.017    |
| Female                            | 26         | 53.1          | 23       | 46.9      |          |
| Age group, years                  |            |               |          |           | 0.008    |
| 60-69                             | 21         | 50.0          | 21       | 50.0      |          |
| 70-79                             | 29         | 69.0          | 13       | 31.0      |          |
| ≥80                               | 4          | 93.3          | 1        | 6.7       |          |
| Hypertension                      |            |               |          |           | 0.602    |
| Yes                               | 58         | 64.4          | 32       | 35.6      |          |
| No                                | 6          | 66.7          | 3        | 33.3      |          |
| Diabetes mellitus                 |            |               |          |           | 0.989    |
| Yes                               | 29         | 64.4          | 16       | 35.6      |          |
| No                                | 35         | 64.8          | 19       | 35.2      |          |
| CRP                               |            |               |          |           | 0.971    |
| Normal                            | 18         | 62.1          | 11       | 37.9      |          |
| Elevated                          | 37         | 61.7          | 23       | 38.3      |          |
| AMI therapy                       |            |               |          |           | 0.502    |
| Clinical management               | 35         | 62.5          | 21       | 37.5      |          |
| Angioplasty                       | 13         | 76.5          | 4        | 23.5      |          |
| Revascularization surgery         | 15         | 60.0          | 10       | 40.0      |          |
| Complications during hospital stay|            |               |          |           | 0.550    |
| Yes                               | 14         | 70.0          | 6        | 30.0      |          |
| No                                | 49         | 62.8          | 29       | 37.2      |          |
| AMI classification                |            |               |          |           | 0.165    |
| STEMI                             | 19         | 76.0          | 6        | 24.0      |          |
| NSTEMI                            | 43         | 60.6          | 28       | 39.4      |          |
| Readmission                       |            |               |          |           | 0.581    |
| Yes                               | 10         | 58.8          | 7        | 41.2      |          |
| No                                | 54         | 65.9          | 28       | 34.1      |          |
| Troponin                          | Median     | IQR           | Median   | IQR       | p value† |
| Sarcopenia                        | 0.11       | 0.03-0.97     | 0.17     | 0.01-0.58 | 0.342    |
| No sarcopenia                     | 0.17       | 0.01-0.58     | 0.17     | 0.01-0.58 | 0.342    |
| CKMB                              | Median     | IQR           | Median   | IQR       | p value† |
| Sarcopenia                        | 6.67       | 2.1-25.0      | 5.5      | 1.7-13.3  | 0.555    |
| No sarcopenia                     | 5.5        | 1.7-13.3      | 5.5      | 1.7-13.3  | 0.555    |
| TIMI                              | Median     | IQR           | Median   | IQR       | p value† |
| Sarcopenia                        | 5.0        | 3.0-5.0       | 3.0      | 2.0-4.0   | 0.002    |
| No sarcopenia                     | 3.0        | 2.0-4.0       | 3.0      | 2.0-4.0   | 0.002    |
| Variable                          | Mean       | SD            | Mean     | SD        | p value† |
| Length of hospital stay           |            |               |          |           | 0.886    |
| Sarcopenia                        | 19.3       | 10.2          | 19.7     | 13.3      |          |
| No sarcopenia                     | 19.7       | 13.3          | 19.7     | 13.3      | 0.886    |

* χ²; † Mann-Whitney U test; ‡ Student’s t test.

CRP: C-reactive protein; AMI: acute myocardial infarction; STEMI: ST elevation acute myocardial infarction; NSTEMI: non-ST elevation acute myocardial infarction; IQR: interquartile range; CKMB: creatine kinase MB isoenzyme; TIMI: thrombolysis in myocardial infarction; SD: standard deviation.
### Table 4. Associations among sarcopenic obesity, sociodemographic and clinical variables, and prognostic markers of coronary heart disease risk in hospitalized elderly patients with coronary heart disease

| Variable                                      | Sarcopenic obesity | No sarcopenic obesity | p value* |
|------------------------------------------------|-------------------|------------------------|----------|
| Sex                                            |                   |                        |          |
| Male                                           | 21                | 43.8                   | 27       | 58.3    | 0.120   |
| Female                                         | 14                | 28.6                   | 35       | 71.4    |
| Age, years                                     |                   |                        |          |
| 60-69                                          | 12                | 28.6                   | 30       | 71.4    | 0.388   |
| 70-79                                          | 17                | 42.5                   | 23       | 57.5    |
| ≥80                                            | 6                 | 40.0                   | 9        | 60.0    |
| Hypertension                                   |                   |                        |          |
| Yes                                            | 34                | 38.6                   | 54       | 61.4    | 0.150   |
| No                                             | 1                 | 11.1                   | 8        | 88.9    |
| Diabetes mellitus                              |                   |                        |          |
| Yes                                            | 18                | 41.9                   | 25       | 58.1    | 0.290   |
| No                                             | 17                | 31.5                   | 37       | 68.5    |
| CRP                                            |                   |                        |          |
| Normal                                         | 13                | 44.8                   | 16       | 55.2    | 0.074   |
| Elevated                                       | 15                | 25.9                   | 43       | 74.1    |
| AMI therapy                                    |                   |                        |          |
| Clinical management                            | 20                | 37.0                   | 34       | 63.0    | 0.776   |
| Angioplasty                                     | 5                 | 29.4                   | 12       | 70.6    |
| Revascularization surgery                      | 10                | 40.0                   | 15       | 60.0    |
| Complications during hospital stay             |                   |                        |          |
| Yes                                            | 6                 | 30.0                   | 14       | 70.0    | 0.500   |
| No                                             | 29                | 38.2                   | 47       | 61.8    |
| AMI classification                              |                   |                        |          |
| STEMI                                          | 9                 | 36.7                   | 16       | 64.0    | 0.882   |
| NSTEMI                                         | 26                | 37.7                   | 43       | 62.3    |
| Readmission                                    |                   |                        |          |
| Yes                                            | 4                 | 23.5                   | 13       | 76.5    | 0.183   |
| No                                             | 31                | 38.8                   | 49       | 61.3    |
| Variable                                       | Sarcopenic obesity | No sarcopenic obesity | p value* |
| Troponin                                       |                   |                        |          |
| Median                                         | 0.06              | 0.02-0.86              | 0.20     | 0.04-0.79 | 0.181   |
| CKMB                                           | 4.0               | 1.4-17.4               | 8.3      | 2.5-19.7 | 0.343   |
| TIMI                                           | 4.0               | 2.0-6.0                | 4.0      | 3.0-5.0  | 0.665   |
| Variable                                       |                   |                        |          |
| Length of hospital stay                        | 20.2              | 11.6                   | 19.2     | 11.1    | 0.669   |

*χ²; † Mann-Whitney U-test; ‡ Student’s t-test. **CVD: Cardiovascular disease.**

## DISCUSSION

Exponential growth of the elderly population has led to increased interest in investigation of age-related complications globally. Sarcopenia and SO are thought to be important risk factors for age-related adverse events, such as increased risk of falls and fractures, higher hospital admission rates and higher mortality. Also, there are evidences to suggest a relation with CVD,(20-22) in spite of the scarcity of studies analyzing the role of these conditions as risk potentiating factors in patients with established CVD. Are there reasons to suspect associations between sarcopenia or SO and increased risk of complications in patients with coronary heart disease?

The sample in this study comprised elderly patients with high CVR, hospitalized due to coronary events...
and with high prevalence of HTN, DM, excess body weight and abdominal obesity. A significant percentage of these patients (76%) had intermediate to high CVR according to post-infarction risk scores TIMI, a sensitive tool for detection of coronary heart disease-related complications. Hence, findings of this study must be interpreted in the light of sample characteristics.

High prevalence of sarcopenia (64.4%) emphasizes the significance of sarcopenia assessment in hospitalized elderly patients with coronary heart disease. Previous investigations suggest the prevalence of sarcopenia in these patients may exceed 50%, as shown by Baumgartner et al.,(1) in a study evaluating Hispanic and non-Hispanic elderly patients with a mean age of 73.6 years, and listed in the health system of New Mexico, USA. A second study based on data of 1,578 individuals aged over 65 years extracted from The Korea National Health and Nutrition Examination Study (KNHANES IV) reported sarcopenia in 30.3% and 29.3% of males and females, respectively. In that study, body composition was determined using dual-energy X-ray absorptiometry (DEXA).(21) Disparities may be attributed to different methods employed to diagnose sarcopenia between studies, or reflect ethnicity-related differences.

According to recent studies, sarcopenia is a risk factor for cardiovascular and/or metabolic complications. In the study by Chin et al.,(21) sarcopenia was considered an independent risk factor, given the higher prevalence of CVD in sarcopenic compared to non-sarcopenic patients (p=0.008). Independent associations between sarcopenia and CVR have also been reported by Han et al.,(23) in a study involving a Chinese population. According to authors of that study,(23) DM and HTN would be major factors associated with sarcopenia, as DM promotes loss of muscle mass and strength in response to hyperglycemia, insulin resistance, endocrine changes and release of inflammatory cytokines. Chronic hyperglycemia leads to increased levels of advanced glycation end-products; these, in turn, accumulate in skeletal muscle and cartilage tissues, increasing muscle stiffness in diabetic patients. Also, inflammatory cytokines, such as tumor necrosis factor and interleukin 6, present in both DM and HTN, have negative impacts on muscle mass and strength and physical performance in older adults.

According to Han et al.,(23) DM and HTN affect muscle mass, muscle strength and physical performance, leading to sarcopenia; however, further studies are needed to elucidate this relation. Lack of associations between DM or HTN and sarcopenia in this study should be emphasized and suggests mechanisms other than DM and HTN may interfere with muscle mass retention and functional capacities.

Severe sarcopenia was detected in 70.3% of sarcopenic patients in this sample. Severe sarcopenia combines loss of muscle mass and strength and functional compromise, increasing the risk of undesirable outcomes, such as higher morbidity and mortality, lower quality of life and higher hospital costs,(3) These findings underscore data derived from studies evaluating elderly patients seen at the general geriatric outpatient clinic of a university hospital, located in the Northeastern region of Brazil, which revealed 66.7% prevalence of severe sarcopenia.(23) In contrast, in a study carried out by Smoliner et al.,(25) at a German hospital, only 25.3% of patients were diagnosed sarcopenia, and the prevalence of severe sarcopenia in this group was low (18.7%). In that study,(25) the sample comprised elderly individuals hospitalized due to general acute conditions and similar criteria to this investigation were employed.

The percentage of sarcopenic obese individuals in this sample (35%) is higher compared to available data on cardiac patients, with most studies reporting less than 10% prevalence.(26-28) However, prevalence may vary widely (0.41%) according to study population and methods employed for definition.(29) Sarcopenic obesity was not associated with coronary heart disease risk parameters in this study. Still, potential relations have been suggested.

Aging in association with decreased levels of physical activity, which, in turn, leads to loss of muscle mass and strength, promoting still lower levels of physical activity and resistance.(33,30) Poor muscle quality with greater fatty infiltration may contribute to higher levels of inflammation. Lower levels of physical activity may lead to weight gain, increased insulin resistance and higher total abdominal fat, with concurrent rise in inflammation levels. Increased production of leptin and other adipokines and cytokines by fat tissue mass may contribute to SO development. The vicious cycle between lean mass loss and fat mass gain may culminate in sarcopenia and SO.(29)

Likewise other studies reporting greater muscle mass in men compared to women, sarcopenia was more pronounced in male and older individuals in this sample. Similar findings have been described by Janssen et al.,(10) in a study reporting 31% and 64% prevalence of sarcopenia in older women and men, respectively. This phenomenon reflects greater loss of muscle mass in response to declining levels of growth hormone, insulin-related growth factor (IGF-1) and testosterone in men; also, men tend to adapt poorly to muscle tissue loss compared to women.(31,32) Increasing sarcopenia with
age is also associated with age-related morphological and functional changes, such as decreased fat-free mass and muscle strength, which lead to sarcopenia.\(^{3,34}\)

Associations between prognostic and coronary heart disease risk markers in this study were limited to TIMI scores, i.e., sarcopenic patients with coronary heart disease scored higher and were, therefore, at greater risk of complications compared to non-sarcopenic elderly patients. Similar analyses are lacking in literature and should be undertaken to corroborate these findings. In any case, sarcopenia is thought to occur concurrently with fat mass increase rather than as an isolated event.\(^{3,21}\) Lipid infiltration contributes to sarcopenia via macrophage-mediated release of pro-inflammatory cytokines and adipokines, which induce chronic inflammation. Sarcopenic individuals tend to have functional and physical impairments associated with lower levels of anti-inflammatory factors induced by muscle contraction — or “myokines”. Relative myokine scarcity in sarcopenia may increase CVD risk. Overall, functional decline and chronic inflammation, as well as lower levels of anti-inflammatory substances in sarcopenic individuals, promote insulin resistance, type 2 DM, hyperlipidemia and hypertension, and may eventually increase the risk of CVD.\(^{21}\) However, these findings must be interpreted with caution, bearing in mind that markers not associated with sarcopenia in this study have not been investigated to date.

Limitations of this study must be emphasized. Retrospective study design relying on medical records may have impacted the analysis due to incomplete or missing data. Relatively small sample size may have limited statistical power. Finally, single center sample comprising a specific group of coronary heart disease patients (AMI patients) limits extrapolation of data to other populations.

**CONCLUSION**

Studies investigating sarcopenia and sarcopenic obesity as markers of coronary heart disease risk are still scarce. This study revealed high prevalence of sarcopenia among patients with coronary heart disease, particularly older male patients. Sarcopenic obesity was less common than sarcopenia; still approximately one-third of patients were affected. Thrombolysis in myocardial infarction score was the only prognostic and cardiovascular diseases risk marker associated with sarcopenia; sarcopenic obesity was not associated with any of the selected markers. Further studies are warranted to elucidate the potential value of sarcopenia and sarcopenic obesity as predictors of complications and prognosis in patients with coronary heart disease. In any case, these conditions are associated with adverse outcomes and should therefore be investigated in routine patient follow-up.

**REFERENCES**

1. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147(8):755-63. Erratum in: Am J Epidemiol. 1998;149(12):1161.
2. Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci. 2002;57(12):M772-7.
3. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland T, Schneider SM, Topinková E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412-23.
4. Goodpaster BH, Carlson CL, Visser M, Kelley DE, Scherzinger A, Harris TB, et al. Attenuation of skeletal muscle mass in the elderly: the health ABC study. J Appl Physiol (1985). 1995;89(6):2157-65.
5. Freitas WM, Carvalho LS, Moura FA, Sposito AC. Atherosclerotic disease in octogenarians: a challenge for science and clinical practice. Atherosclerosis. 2012;225(2):281-9. Review.
6. Kim TN, Choi KM. The implications of sarcopenia and sarcopenic obesity on cardiometabolic disease. J Cell Biochem. 2015;116(7):1171-8. Review.
7. Atkins JA, Wannamethee G. The effect of sarcopenia on cardiovascular disease and all-cause mortality in older people. Rev Clin Gerontol. 2015;25(2):86-97.
8. Janssen I, Heymsfield SB, Baumgartner RN, Ross R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol (1985). 2000;89(2):465-71.
9. Kuczynski MF, Kuczmarski RJ, Najjar M. Descriptive anthropometric reference data for older Americans. J Am Diet Assoc. 2000;100(1):59-66.
10. Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol. 2004;159(4):413-21.
11. Laupacis A, Starfield B, Cram P, Le Rosen D, Causton H, Elishuk WJ, et al. Age-associated changes in skeletal muscles and their effect on mobility: an observational diagnosis of sarcopenia. J Appl Physiol (1985). 2003;95(5):1851-60.
12. Abellan van Kan G, Cederbaum JM, Cersi JM, Dahinden F, Fariello RG, Fielding RA, et al.; Sarcopenia: biomarkers and imaging (International Conference on Sarcopenia research). J Nutr Health Aging. 2011;15(10):834-46.
13. Stenholm S, Harris TB, Bantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care. 2008;11(6):693-700. Review.
14. World Health Organization (WHO). Obesity: preventing and managing the global epidemic. Report of a WHO Consultation [Internet]. Geneva: WHO Technical Report Series 894. World Health Organization, 1998 [cited 2018 Aug 14]. Available from: whqlibdoc.who.int/trs/WHO_TRS_894.pdf

**AUTHORS’ INFORMATION**

Santana NM: http://orcid.org/0000-0002-9574-2239
Mendes RM: http://orcid.org/0000-0002-9750-2992
Silva NF: http://orcid.org/0000-0002-3664-6132
Pinho CP: http://orcid.org/0000-0002-5689-5048
Sarcopenia and sarcopenic obesity as prognostic predictors in hospitalized elderly patients with acute myocardial infarction

15. Wang Z, Hoy WE. Waist circumference, body mass index, hip circumference and waist-to-hip ratio as predictors of cardiovascular disease in Aboriginal people. Eur J Clin Nutr. 2004;58(6):888-93.

16. Bosy-Westphal A, Booke CA, Blöcker T, Kossel E, Goele K, Later W, et al. Measurement site for waist circumference affects its accuracy as an index of visceral and abdominal subcutaneous fat in a Caucasian population. J Nutr. 2010;140(5):954-61.

17. Pereira JL, Sakae TM, Machado MC, Castro CM. TIMI risk score for acute myocardial infarction according to prognostic stratification. Arq Bras Cardiol. 2009;93(2):105-12.

18. Olinto MT, Nacúl LC, Dias-da-Costa JS, Gigante DP, Macedo S. Niveis de intervenção para obesidade abdominal: prevalência e fatores associados. Cad Saúde Pública. 2006;22(6):1207-15.

19. Lipschitz DA. Screening for nutritional status in the elderly. Prim Care. 1994;21(1):55-67. Review.

20. Janssen I, Heymsfield SB, Baumgartner RN, Ross R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol. 2009;89(2):465-71.

21. Chin SO, Rhee SY, Chon S, Hwang YC, Jeong IK, Oh S, et al. Sarcopenia is independently associated with cardiovascular disease in older Korean adults: the Korea National Health and Nutrition Examination Survey (KNHANES) from 2009. PLoS One. 2013;8(3):e60119.

22. Atkin JL, Whincup PH, Morris RW, Wannamethee SG. Low muscle mass in older men: The role of lifestyle, diet and cardiovascular risk factors. J Nutr Health Aging. 2014;18(1):26-33.

23. Han P, Yu H, Ma Y, Kang L, Fu L, Jia L, et al. The increased risk of sarcopenia in patients with cardiovascular risk factors in Suburb-Dwelling older Chinese using the AWGS definition. Sci Rep. 2017;7(1):9592.

24. Santos AD, Pinho CP, Nascimento AC, Costa AC. Sarcopenia en pacientes ancianos atendidos ambulatoriamente: prevalencia y factores asociados. Nutr Hosp. 2016;33(2):255-62.

25. Smoliner C, Sieber CC, Wirth R. Prevalence of sarcopenia in geriatric hospitalized patients. J Am Med Dir Assoc. 2014;15(4):267-72.

26. Newman AB, Kupelian V, Visser M, Simonsick E, Goodpater B, Nevitt M, Kritchevsky SB, Tylavsky FA, Rubin SM, Harris TB; Health ABC Study Investigators. Sarcopenia: alternative definitions and associations with lower extremity function. J Am Geriatr Soc. 2003;51(11):1602-9.

27. Bouchard DR, Dionne LJ, Brochu M. Sarcopenic Obesity and Physical capacity in older men and women: data From the Nutrition as a Determinant of Successful Aging (NuAge)-the Quebec Longitudinal Study. Obesity (Silver Spring). 2009;17(11):2082-8.

28. Rolland Y, Lauwers-Cances V, Cournot M, Nourhashemi F, Reynish W, Riviere D, et al. Sarcopenia, calf circumference, and physical function of elderly women: a cross-sectional study. J Am Geriatr Soc. 2003;51(8):1120-4.

29. Cauley JA. An Overview of Sarcopenic Obesity. J Clin Densitom. 2015;18(4):499-505. Review.

30. Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR, Harris TB. Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos Int. 2010;21(4):543-59. Review.

31. Leite LE, Resende TI, Nogueira GM, Cruz IB, Scheider RH, Gottlieb MG. Envelhecimento, estresse oxidativo e sarcopenia: uma abordagem sistêmica. Rev Bras Geriatr Gerontol. 2012;15(2):29-35.

32. Meng P, Hu YX, Fan L, Zhang MX, Sun J, Liu Y, et al. Sarcopenia and sarcopenic obesity among men aged 80 years and older in Beijing: prevalence and its association with functional performance. Geriatr Gerontol Int. 2014;14(Suppl 1):29-35.

33. Oliveira RJ, Bottaro M, Júnior JT, Farinatti PT, Bezerra LA, Lima RM. Identification of sarcopenic obesity in postmenopausal women: a cutoff proposal. Braz J Med Biol Res. 2011;44(11):1171-6.

34. Silva Neto LS, Karnikowski MG, Tavares AB, Lima RM. Association between sarcopenia, sarcopenic obesity, muscle strength and quality of life variables in elderly women. Rev Bras Fisioter. 2012;16(5):360-7.